Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Lilly And J&J Are Readying NGF Inhibitors For Phase III

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer and Lilly plan to resume Phase III testing of their nerve growth factor inhibitor after FDA lifted a partial hold on tanezumab. But J&J is also poised to run new Phase III studies with fulranumab.

Advertisement

Related Content

Lilly Shows Off R&D Progress With A Pain Franchise Built On New Mechanisms
Pfizer Plans To Restart Tanezumab Trials In 2014
Anti-NGF Trials Might Resume With Very Narrow Patient Populations
Regeneron, J&J, AstraZeneca Pull Plug On NGF Inhibitors In Development For Pain Indications
Future Appears Grim For Pfizer's Tanezumab With Ostearthritis Trial Stopped
A Painstaking Approach: Can Anti-NGFs Give Relief To Pharma Pipeline Woes?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS078293

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel